Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trialYing–Hong Shi, Enxiao Li, Weidong Jia et al.|The Lancet. Gastroenterology & hepatology|2025Cited by 39
CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trialJia Liu, Lin Shen, Jianwei Yang et al.|Nature Medicine|2025Cited by 29